Advertisement

Thermo Fisher Scientific Inc. TMO

Set alert

Price alert · TMO

All alert types
697.00 USD -12.18 -1.72%

At close · Oct 30

696.18 -0.82 -0.12%

After hours · Oct 30, 7:00 PM ET

Bid
696.77 × 80
Ask
697.07 × 80
691.74 Day range 711.79
438.34 52-week range 709.18
YTD
+20.29%
1 year
+25.31%
Open
710.69
Prev close
709.18
Mkt cap
257.71B
Vol
2.09M
Avg vol
2.09M
EPS
18.96
P/E
36.76
Div yield
0.27%
More statistics
Low
691.74
High
711.79
Forward P/E
25.11
Beta
0.88
Short ratio
1.98
Inst. own
93.55%
Dividend
1.88
Ex-div date
Sep 14, 2026
Earnings
Feb 4, 2027
50-d avg
653.26
200-d avg
550.99
1y target
752.12

MAX chart

Chart tools
Interval

Events in this range
  • Jun 6, 1996Split: 3 for 2
  • Oct 30, 2026Rating: Argus Research · Buy → Buy
Signals (48)
NameDateAgo
MACD: Buy SignalOct 30, 20261 day ago
SMA: BullishJun 1, 20265 months ago
SMA: BearishDec 1, 202511 months ago
SMA: BullishSep 1, 20251 year ago
SMA: BullishJun 1, 20251 year ago
SMA: BearishMar 1, 20251 year ago
SMA: BearishSep 1, 20242 years ago
SMA: BullishDec 1, 20232 years ago
SMA: BearishSep 1, 20233 years ago
SMA: BullishJun 1, 20233 years ago
SMA: BearishMar 1, 20233 years ago
MACD: Sell SignalMar 1, 20233 years ago
RSI: OverboughtDec 1, 20169 years ago
RSI: OverboughtMar 1, 201610 years ago
RSI: OverboughtJun 1, 201313 years ago
MACD: Buy SignalSep 1, 201214 years ago
SMA: BullishJun 1, 201214 years ago
SMA: BearishMar 1, 201214 years ago
SMA: BullishDec 1, 201114 years ago
SMA: BearishSep 1, 201115 years ago
MACD: Sell SignalSep 1, 201115 years ago
MACD: Buy SignalMar 1, 201115 years ago
SMA: BullishSep 1, 201016 years ago
SMA: BearishJun 1, 201016 years ago
SMA: BullishDec 1, 200916 years ago
MACD: Sell SignalDec 1, 200817 years ago
SMA: BearishSep 1, 200818 years ago
RSI: OverboughtSep 1, 200620 years ago
SMA: BullishDec 1, 200322 years ago
MACD: Buy SignalSep 1, 200323 years ago
SMA: BullishJun 1, 200323 years ago
SMA: BearishDec 1, 200124 years ago
SMA: BearishJun 1, 200125 years ago
MACD: Sell SignalJun 1, 200125 years ago
MACD: Buy SignalMar 1, 200125 years ago
SMA: BullishSep 1, 200026 years ago
SMA: BullishJun 1, 200026 years ago
SMA: BearishJun 1, 199828 years ago
SMA: BearishMar 1, 199828 years ago
MACD: Sell SignalMar 1, 199828 years ago
RSI: OverboughtDec 1, 199728 years ago
RSI: OverboughtJun 1, 199729 years ago
RSI: OverboughtJun 1, 199432 years ago
RSI: OverboughtDec 1, 199233 years ago
SMA: BullishSep 1, 199036 years ago
SMA: BearishJun 1, 199036 years ago
SMA: BullishDec 1, 198837 years ago
SMA: BearishSep 1, 198739 years ago

Key statistics

Market cap
257.70B
Enterprise value
297.83B
Trailing P/E
36.76
Forward P/E
25.11
PEG ratio
2.10
Price / sales
5.44
Price / book
4.71
EPS (TTM)
18.96
Beta
0.88
Dividend yield
0.27%
Payout ratio
9.69%
Profit margin
14.94%
Revenue (TTM)
47.35B
Revenue growth
9.10%
Free cash flow
6.45B
Total cash
6.06B
Total debt
41.37B
Return on equity
13.38%
Shares outstanding
369.75M
Short % of float
1.32%
50-day average
653.26
200-day average
550.99

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 752.12 +7.9% upside
Target (low)
590.00
Target (mean)
752.12
Target (high)
830.00
Ratings (0m) 27 23 buy · 3 hold · 1 sell
  • Strong buy3
  • Buy20
  • Hold3
  • Sell0
  • Strong sell1

Next earnings

Feb 4, 2027

Expected Feb 4, 2027. Consensus EPS estimate 7.14.

Earnings history

Financials — quick view

All financials
TMO Revenue — quarterly 11.99B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TMO Net income — quarterly 1.74B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TMO EPS — quarterly 4.68
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

TMO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 26, 20267.15———
Oct 21, 2026Sep 26, 20266.406.68+0.28+4.37%
Jul 23, 2026Jun 27, 20265.726.03+0.31+5.42%
Apr 23, 2026Mar 28, 20265.255.44+0.19+3.62%
Jan 29, 2026Dec 31, 20256.456.57+0.12+1.86%
Oct 22, 2025Sep 27, 20255.505.79+0.29+5.27%

Upgrades / downgrades

TMO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026Argus ResearchmainBuyBuy
Oct 23, 2026CitigroupmainBuyBuy
Oct 22, 2026BarclaysmainOverweightOverweight
Oct 22, 2026RBC CapitalmainSector PerformSector Perform
Oct 22, 2026TD CowenmainBuyBuy
Oct 22, 2026StifelmainBuyBuy

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on TMO — it syncs with the Stock Master app.

Insider holders

TMO insider holders
InsiderRelationLatest transactionDateShares held
BOXER MICHAEL AGeneral CounselSaleMar 9, 202510,815
BRITT LISA POfficerSaleAug 18, 202614,784
CASPER MARC NChief Executive OfficerSaleAug 23, 2026140,225
CHAI NELSON JDirectorStock Award(Grant)May 19, 202615,316
LAGARDE MICHELChief Operating OfficerStock Award(Grant)Feb 24, 202686,347
LOWERY FREDERICK M.OfficerStock Award(Grant)Feb 24, 202617,133

Institution ownership

TMO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.36%30,919,63221.55BJun 29, 2026
Vanguard Capital Management LLC6.57%24,276,31616.92BJun 29, 2026
State Street Corporation4.55%16,825,87911.73BJun 29, 2026
FMR, LLC3.81%14,084,4889.82BJun 29, 2026
Morgan Stanley2.91%10,763,0667.50BJun 29, 2026
JPMORGAN CHASE & CO2.30%8,503,5275.93BJun 29, 2026

Fund ownership

TMO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%11,797,8008.22BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%9,628,7136.71BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%4,926,5073.43BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%4,823,9753.36BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%4,572,5553.19BSep 29, 2026
Fidelity Contrafund1.12%4,123,9662.87BAug 30, 2026
Advertisement